Barclays Maintains Overweight on Kura Oncology, Lowers Price Target to $11

Benzinga · 05/02 13:51
Barclays analyst Peter Lawson maintains Kura Oncology (NASDAQ:KURA) with a Overweight and lowers the price target from $32 to $11.